BioStock: PHI charts a bold course to impact regenerative medicine

Swedish medtech company PHI released its year-end report last week, outlining its transformative phase and strategic focus on regenerative medicine and clinical applications. To delve into the report's highlights and shed light on the company's vision and initiatives, BioStock contacted CEO Patrik Eschricht.

Read the interview with PHI's CEO Patrik Eschricht at biostock.se:

https://www.biostock.se/en/2023/07/phi-charts-a-bold-course-to-impact-regenerative-medicine/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/